ADANI GREEN
Adani Renewable Energy (GJ) Limited, a stepd.own subsidiary of Adani Green Energy Limited ("AGEL") has commissioned its 75 MW Wind Power Project having Power Purchase Agreement ("PPA") with Maharashtra State Electricity Distribution Company Limited ("MSEDCL") at Rs. 2.85/kWh for a period of 25 years. Commercial sale of power from the Project to MSEDCL is expected to commence w.e.f. 1st January, 2020.
With this, 2.50 GWac of renewable energy projects are operational. AGEL has total 5.29 GWac portfolio of renewable capacity in India, out of which 2.79 GWac projects are under implementation.
HERO MOTOCORP
HERO MOTOCORP INTRODUCES COUNTRY’S FIRST 100-CC BS-VI MOTORCYCLE – HF DELUXE BS-VI POWERED BY PROGRAMMED FI WITH ‘XSENS TECHNOLOGY’
ATTRACTIVELY PRICED @ RS. 55,925/-
INDOCO REMEDIES
Indoco receives Approval for Febuxostat Tablets from USFDA
Indoco Remedies received final approval of its ANDA for Febuxostat Tablets 40 mg and 80 mg, which is therapeutically equivalent to the Reference Listed Drug (RLD), viz., Uloric Tablets 40 mg and 80 mg of Takeda Pharmaceuticals U.S.A., Inc.
The market size of Febuxostat tablets in USA is over USD 500 million.
Febuxostat is used for the treatment of gout caused by excessive levels of uric acid in the blood
(Hyperuricemia). Febuxostat prevents the production of uric acid by blocking the activity of the
enzyme (xanthine oxidase) that converts purines to uric acid. Uric acid forms crystals in jointstissues, causing inflammation and pain. Hyperuricemia can cause kidney disease and kidney stones as
well.